<DOC>
	<DOCNO>NCT02582970</DOCNO>
	<brief_summary>This expand access study ass efficacy safety intravenous ( IV ) bevacizumab combination chemotherapy regimens first-line treatment metastatic cancer colon rectum . The anticipated median time study treatment approximately 10 month , target sample size 40 individual .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Combination With Chemotherapy Participants With Metastatic Cancer Colon Rectum</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Previously untreated metastatic colon rectal cancer Scheduled begin IV 5fluorouracilbased chemotherapy firstline treatment Prior chemotherapy metastatic colon rectal cancer Planned radiotherapy underlie disease Central nervous system metastases Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study start Treatment investigational drug , participation another investigational study , within 30 day prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>